After the failure of the Pfizer-AstraZeneca transaction at the end of May, the two companies have now announced new deals with other companies. But the two drugs companies could return to the proposed inversion deal later this year.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
Like medicine, tax is an evolving science. Norah Al Khalaf explains how tax policies have changed across the member states of the Gulf Cooperation Council and what tax departments should prepare for next.